ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BMS Adds Tau Antibody With iPierian Deal

by Lisa M. Jarvis
May 5, 2014 | APPEARED IN VOLUME 92, ISSUE 18

Bristol-Myers Squibb has paid $175 million in cash, with the promise of up to $550 million in milestones, to acquire privately held iPierian. With the deal, BMS gains the rights to IPN007, an antibody aimed at progressive supranuclear palsy (PSP) and other neurodegenerative diseases associated with the buildup of tau, a protein believed to help regulate the activity of brain cells. IPN007 is expected to enter Phase I studies in early 2015 as a treatment for PSP, but it has the potential to be useful in treating Alzheimer’s disease.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment